Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://www.ncbi.nlm.nih.gov/pubmed/27776353
http://dx.doi.org/10.18632/oncotarget.12786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://www.ncbi.nlm.nih.gov/pubmed/27776353
http://dx.doi.org/10.18632/oncotarget.12786

Ejemplares similares